How Does Femodene Work in the Body
Chemical Composition, Mechanism of Action & Metabolic Effects Explained
Key Takeaways: How Femodene Works
- Active Ingredients: Gestodene (75μg progestogen) and ethinylestradiol (30μg oestrogen).
- Triple Mechanism: Prevents ovulation, thickens cervical mucus, and thins the endometrium.
- Onset & Duration: Immediate contraceptive effect if started on day 1 of cycle; 7‑day pill‑free interval maintains cycle control.
- Metabolism: Both hormones are metabolised in the liver (CYP3A4) and excreted via urine and faeces.
- Additional Benefits: Regularises periods, reduces menstrual pain, and may decrease risk of ovarian and endometrial cancer with long‑term use.
Femodene is a monophasic combined oral contraceptive containing gestodene and ethinylestradiol. It prevents pregnancy through three complementary actions: inhibition of ovulation, alteration of cervical mucus, and endometrial changes. Below we explore the precise pharmacology behind each effect.
Important Medical Advice
Seek urgent medical attention if you experience sudden leg swelling/pain, unexplained chest pain, breathlessness, severe headache, or visual disturbances — these could be signs of a blood clot. Also stop Femodene and consult a doctor immediately if you develop jaundice, severe upper abdominal pain, or a breast lump.
Chemical Composition & Molecular Structure
Femodene tablets contain two active steroid hormones: gestodene (a third‑generation progestogen) and ethinylestradiol (a synthetic oestrogen). Each white sugar‑coated tablet provides 75 micrograms of gestodene and 30 micrograms of ethinylestradiol. The excipients include lactose, maize starch, povidone, magnesium stearate, sucrose, and calcium carbonate, which form the tablet core and coating.
Structural Details
13‑ethyl‑17β‑hydroxy‑18,19‑dinor‑17α‑pregna‑4,15‑dien‑20‑yn‑3‑one
A 19‑nortestosterone derivative with high progestogenic activity and minimal androgenic effect. Its 15‑ene structure enhances receptor binding affinity and prolongs half‑life.
19‑nor‑17α‑pregna‑1,3,5(10)‑trien‑20‑yne‑3,17‑diol
A synthetic oestrogen with an ethinyl group at C17, which slows hepatic metabolism and makes it orally active. It is the standard oestrogen component in most combined pills.
Key Pharmaceutical Properties
| Property | Gestodene | Ethinylestradiol |
|---|---|---|
| Lipophilicity (logP) | 3.5 | 4.1 |
| Protein binding | 75–80% (SHBG, albumin) | 98% (albumin) |
| Oral bioavailability | ~99% | ~45% (first‑pass effect) |
| Receptor affinity | High (progesterone receptor) | High (oestrogen receptor α/β) |
🗒️ Pharmaceutical insight: Gestodene is unique among progestogens because it does not require hepatic activation and has a high relative binding affinity for the progesterone receptor, contributing to its potent ovulation‑inhibiting effect at low doses.
Mechanism of Action: Dual Hormonal Pathway
Femodene’s contraceptive efficacy results from three synergistic mechanisms, each mediated by the two hormones.
- Ovulation inhibition (primary mechanism): Ethinylestradiol suppresses FSH, preventing follicle development. Gestodene inhibits the LH surge, thereby blocking ovulation. This central action is the most reliable component.
- Cervical mucus thickening: Gestodene increases the viscosity and spinbarkeit of cervical mucus, forming a physical barrier that impedes sperm penetration and capacitation.
- Endometrial alteration: The combination induces an atrophic, secretory‑inactive endometrium that is unreceptive to implantation, providing a third layer of protection.
| Target | Gestodene Role | Ethinylestradiol Role |
|---|---|---|
| Hypothalamus/pituitary | Suppresses LH surge | Suppresses FSH, stabilises endometrium |
| Cervical mucus | Thickens mucus, reduces sperm penetration | No direct effect |
| Endometrium | Induces atrophy, reduces glandular development | Enhances progestogen effect, prevents breakthrough bleeding |
🗒️ Physiological insight: The combination also causes subtle changes in tubal motility and possibly sperm transport, though these are secondary to the main mechanisms.
Absorption & Distribution (Pharmacokinetics)
Following oral administration, both hormones are rapidly absorbed from the gastrointestinal tract.
Gestodene absorption
Peak plasma concentrations occur within 2‑4 hours. It is almost completely bioavailable due to minimal first‑pass metabolism. In the circulation, 75‑80% is bound to sex hormone‑binding globulin (SHBG) and albumin. SHBG levels increase during Femodene use, further influencing distribution.
Ethinylestradiol absorption
Peak levels reached in 1.5‑2 hours. Extensive first‑pass metabolism in the gut wall and liver reduces absolute bioavailability to ~45%. It is highly bound to albumin (98%) and induces hepatic synthesis of SHBG, which in turn affects gestodene distribution.
Both hormones cross the placenta and are excreted in breast milk in negligible amounts (not sufficient to affect an infant).
Metabolic Effects & Elimination
Gestodene is extensively metabolised in the liver, primarily by CYP3A4, via reduction and hydroxylation, followed by conjugation. The metabolites are pharmacologically inactive. Excretion is approximately 50% in urine and 33% in faeces, with an elimination half‑life of 12‑15 hours.
Ethinylestradiol undergoes aromatic hydroxylation (CYP3A4) and conjugation (glucuronidation/sulfation). It also undergoes enterohepatic recirculation, which contributes to its longer half‑life (12‑18 hours). About 40% is excreted in urine and 60% in faeces.
⚠️ Metabolic caution: Drugs that induce CYP3A4 (e.g., rifampicin, certain anticonvulsants, St John’s Wort) can accelerate metabolism of both hormones, potentially reducing contraceptive efficacy. Conversely, inhibitors may increase exposure.
Effects on Laboratory Parameters
Femodene increases SHBG concentration (2‑ to 4‑fold), slightly raises HDL cholesterol, and may alter coagulation factors. These changes are generally not clinically significant in healthy women but contribute to the thrombotic risk discussed in the PIL.
Clinical Efficacy in Contraception
When taken correctly (one pill daily for 21 days, followed by a 7‑day pill‑free interval), Femodene has a Pearl Index of <1 (less than 1 pregnancy per 100 woman‑years). Typical‑use failure rates are higher (≈3‑9%) due to missed pills or drug interactions.
Non‑contraceptive benefits: Users often experience more regular, lighter, and less painful periods. Long‑term use (≥5 years) is associated with reduced risk of ovarian and endometrial cancer. The pill does not protect against STIs; barrier methods are advised for additional protection.
The 7‑day pill‑free interval reliably induces withdrawal bleeding, usually starting 2‑3 days after the last active pill. If pills are missed, the risk of ovulation increases, and supplementary contraception or emergency contraception may be required (see section 3.3 of the PIL).
Femodene FAQs
How quickly does Femodene start working?
If started on day 1 of your period, protection begins immediately. If started later, use additional contraception (e.g., condoms) for the first 7 days.
Can I take Femodene if I smoke?
Smoking increases the risk of serious cardiovascular side effects, especially over age 35. If you smoke, your doctor may advise a non‑hormonal method.
What should I do if I miss a pill?
If you're less than 12 hours late, take it immediately and continue normally. If more than 12 hours late, follow the PIL instructions: take the last missed pill, use condoms for 7 days, and consider emergency contraception if you had unprotected sex.
Does Femodene cause weight gain?
Weight gain is reported by some users but is usually modest. Large studies show no consistent causal link; any change is often temporary.
Can I take Femodene while breastfeeding?
Combined pills are generally not recommended during breastfeeding because oestrogen may reduce milk supply. Progestogen‑only methods are preferred.
Need Femodene with Expert Guidance?
If you're considering Femodene for contraception, a UK‑registered doctor can review your medical history and provide a prescription after an online consultation.
Secure Prescription & Next‑Day Delivery
MHRA‑compliant | GPhC‑registered pharmacy | Discreet packaging | UK‑registered doctors
Start Contraception ConsultationRelated Femodene Guides
Medical Content Manager
Nabeel is a co‑founder and medical content manager of Chemist Doctor. He works closely with our medical team to ensure the information is accurate and up‑to‑date.
Medical Doctor
Dr. Feroz is a GMC‑registered doctor and a medical reviewer at Chemist Doctor. He oversees acute condition and urgent care guidance.
Medical Director
Usman is a co‑founder and medical director of Chemist Doctor. He leads the organisation's strategic vision, bridging clinical and operational priorities.
Review Date: 15 March 2026
Next Review: 15 September 2026
Published on: 15 March 2026
Last Updated: 15 March 2026